Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

Saved in:

Bibliographic Details
Published in	Annals of oncology Vol. 27; p. vi313
Main Authors	Weisel, K., Palumbo, A., Chanan-Khan, A., Nooka, A.K., Spicka, I., Masszi, T., Beksac, M., Hungria, V., Munder, M., Mateos, M.-V., Mark, T.M., Spencer, A., Qi, M., Schecter, J., Amin, H., Qin, X., Deraedt, W., Ahmadi, T., Sonneveld, P.
Format	Journal Article
Language	English
Published	Elsevier Ltd 01.10.2016
Online Access	Get full text

Loading…

More Information
ISSN:	0923-7534 1569-8041
DOI:	10.1093/annonc/mdw375.01